Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
Melikian GL, Rhee SY, Varghese V, Porter D, White K, Taylor J, Towner W, Troia P, Burack J, Dejesus E, Robbins GK, Razzeca K, Kagan R, Liu TF, Fessel WJ, Israelski D, Shafer RW. Melikian GL, et al. J Antimicrob Chemother. 2014 Jan;69(1):12-20. doi: 10.1093/jac/dkt316. Epub 2013 Aug 9. J Antimicrob Chemother. 2014. PMID: 23934770 Free PMC article.
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T. Cohen C, et al. AIDS. 2014 Apr 24;28(7):989-97. doi: 10.1097/QAD.0000000000000169. AIDS. 2014. PMID: 24508782 Clinical Trial.
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Palella FJ Jr, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, Shamblaw D, Flamm J, Ebrahimi R, Porter D, White K, Hindman J, Elbert E, De-Oertel S, Fralich T. Palella FJ Jr, et al. AIDS. 2014 Jan 28;28(3):335-44. doi: 10.1097/QAD.0000000000000087. AIDS. 2014. PMID: 24670520 Clinical Trial.
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL. Porter DP, et al. HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585. HIV Clin Trials. 2016. PMID: 26899540 Clinical Trial.
69 results